Peter Bond discusses enclomiphene and explains what went wrong in the attempt to gain FDA approval as a treatment for hypogonadism:
"Repros Therapeutics Inc, made an attempt at making a SERM approved by the FDA for the treatment of secondary hypogonadism. Before I continue about how this process went, I’d like to provide some background on their SERM: enclomiphene citrate (brand name Androxal, later rebranded to EnCyzix)."
thinksteroids.com
"Repros Therapeutics Inc, made an attempt at making a SERM approved by the FDA for the treatment of secondary hypogonadism. Before I continue about how this process went, I’d like to provide some background on their SERM: enclomiphene citrate (brand name Androxal, later rebranded to EnCyzix)."
Enclomiphene - A SERM That was Seeking FDA Approval for the Treatment of Hypogonadism - MESO-Rx
Repros Therapeutics Inc, made an attempt at making a SERM approved by the FDA for the treatment of secondary hypogonadism. Before I continue about how this process went, I’d like to provide some background on their SERM: enclomiphene citrate (brand name Androxal, later rebranded to EnCyzix).
thinksteroids.com
